

## Texas Standard Prior Authorization Form Addendum

## **Molina Healthcare of Texas**

Zelboraf (Vemurafenib) (Medicaid)

This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review information, sign, and date. Fax signed forms to Molina Pharmacy Prior Authorization Department at **1-888-487-9251**. Please contact Molina Pharmacy Prior Authorization Department at **1-855-322-4080** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Zelboraf (Vemurafenib) (Medicaid).

Drug Name (select from list of drugs shown / provide drug information)								
ZELBORAF 240MG TABLET								
Patient Information								
Pa	tient Name:							
Pa	tient ID:							
Pa	tient DOB:							
Prescribing Physician								
Physician Name:								
Physician Phone:								
Physician Fax:								
Physician Address:								
Cit	ty, State, Zip:							
Diagnosis:			ICD Code:					
Directions for administration:								
***Please include all relevant clinical notes, lab work, medication history and any other applicable documentation.  Please circle the appropriate answer for each question.								
1. Is the requested drug required per court order? (court order required)  If the answer to this question is yes, approved for 365 days.  If the answer to this question is no, go to question 2.			Y	N				
2. Is the medication being prescribed by, or its use being overseen by, an oncologist? If the answer to this question is yes, go to question 3. If the answer to this question is no, denied.				Y	N			
3. Does the patient have a diagnosis of unresectable or metastatic melanoma or Erdheim-Chester disease in the last 365 days?  If the answer to this question is yes, go to question 4.  If the answer to this question is no, denied.			Y	N				
4. Has the presence of the BRAF V600E mutation been confirmed? If the answer to this question is yes, go to question 5. If the answer to this question is no, denied.		Y	N					

Prescriber (or Authorized) Signature  Date			_
I a	ffirm that the information given on this form is true and accurate as of this date.		
Co	omments:		
9.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, denied.	Y	ľ
8.	Is there a documented allergy or contraindication to preferred agents in this class? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 9.	Y	ľ
7.	Has the patient failed a treatment trial with at least 1 preferred agent? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 8.	Y	1
6.	Is the request for a non-preferred drug?  If the answer to this question is yes, go to question 7.  If the answer to this question is no, approved for 365 days.	Y	ľ
5.	Does the patient have 1 claim for a strong CYP3A4 inhibitor/inducer or a CYP1A2 substrate with a narrow therapeutic index in the last 90 days?  If the answer to this question is yes, denied.  If the answer to this question is no, go to question 6.	Y	ľ